- Home
- ENTX vs INO Comparison
ENTX vs INO Comparison
Compare ENTX & INO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ENTX | INO |
|---|---|---|
| Founded | 2010 | 1979 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 142.0M | 136.6M |
| IPO Year | 2018 | 1998 |
Fundamental Metrics
Financial Performance| Metric | ENTX | INO |
|---|---|---|
| Price | $2.16 | $2.06 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $10.00 | $9.00 |
| AVG Volume (30 Days) | 82.8K | ★ 1.2M |
| Earning Date | 11-14-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $124,000.00 | ★ $182,337.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $21,219.94 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 25.25 | N/A |
| 52 Week Low | $1.50 | $1.30 |
| 52 Week High | $3.22 | $4.44 |
Technical Indicators
Market Signals| Indicator | ENTX | INO |
|---|---|---|
| Relative Strength Index (RSI) | 36.71 | 51.22 |
| Support Level | $2.05 | $1.86 |
| Resistance Level | $2.53 | $2.10 |
| Average True Range (ATR) | 0.22 | 0.12 |
| MACD | -0.07 | 0.03 |
| Stochastic Oscillator | 13.42 | 89.74 |
Price Performance
Historical ComparisonAbout ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
About INO Inovio Pharmaceuticals Inc.
Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.